345 related articles for article (PubMed ID: 23372686)
81. DNA binding partners of YAP/TAZ.
Kim MK; Jang JW; Bae SC
BMB Rep; 2018 Mar; 51(3):126-133. PubMed ID: 29366442
[TBL] [Abstract][Full Text] [Related]
82. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
[TBL] [Abstract][Full Text] [Related]
83. Substratum stiffness and latrunculin B modulate the gene expression of the mechanotransducers YAP and TAZ in human trabecular meshwork cells.
Thomasy SM; Morgan JT; Wood JA; Murphy CJ; Russell P
Exp Eye Res; 2013 Aug; 113():66-73. PubMed ID: 23727052
[TBL] [Abstract][Full Text] [Related]
84. PTBP1-mediated regulation of AXL mRNA stability plays a role in lung tumorigenesis.
Cho CY; Chung SY; Lin S; Huang JS; Chen YL; Jiang SS; Cheng LC; Kuo TH; Lay JD; Yang YY; Lai GM; Chuang SE
Sci Rep; 2019 Nov; 9(1):16922. PubMed ID: 31729427
[TBL] [Abstract][Full Text] [Related]
85. Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.
Lozneanu L; Pinciroli P; Ciobanu DA; Carcangiu ML; Canevari S; Tomassetti A; Căruntu ID
Anticancer Res; 2016 Aug; 36(8):4155-63. PubMed ID: 27466525
[TBL] [Abstract][Full Text] [Related]
86. Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours.
Green J; Ikram M; Vyas J; Patel N; Proby CM; Ghali L; Leigh IM; O'Toole EA; Storey A
Br J Cancer; 2006 May; 94(10):1446-51. PubMed ID: 16641895
[TBL] [Abstract][Full Text] [Related]
87. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
88. CRISPR-Mediated Approaches to Regulate YAP/TAZ Levels.
Quinton RJ; Ganem NJ
Methods Mol Biol; 2019; 1893():203-214. PubMed ID: 30565136
[TBL] [Abstract][Full Text] [Related]
89. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
[TBL] [Abstract][Full Text] [Related]
90. AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.
Axelrod HD; Valkenburg KC; Amend SR; Hicks JL; Parsana P; Torga G; DeMarzo AM; Pienta KJ
Mol Cancer Res; 2019 Feb; 17(2):356-369. PubMed ID: 30291220
[TBL] [Abstract][Full Text] [Related]
91. VASN promotes colorectal cancer progression by activating the YAP/TAZ and AKT signaling pathways via YAP.
Liang W; Zuo J; Liu M; Su Y; Guo B; Hou J; Xing Q; Peng Y; Fang L; Cao Y; Shan J; Sun R; Zhao J; Wang J
FASEB J; 2023 Jan; 37(1):e22688. PubMed ID: 36468780
[TBL] [Abstract][Full Text] [Related]
92. AXL phosphorylates and up-regulates TNS2 and its implications in IRS-1-associated metabolism in cancer cells.
Cheng LC; Chen YL; Cheng AN; Lee AY; Cho CY; Huang JS; Chuang SE
J Biomed Sci; 2018 Nov; 25(1):80. PubMed ID: 30419905
[TBL] [Abstract][Full Text] [Related]
93. ZNF224 is a transcriptional repressor of AXL in chronic myeloid leukemia cells.
Sodaro G; Blasio G; Fiorentino F; Auberger P; Costanzo P; Cesaro E
Biochimie; 2018 Nov; 154():127-131. PubMed ID: 30176265
[TBL] [Abstract][Full Text] [Related]
94. The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras-MAPK Signaling in Epithelioid Hemangioendothelioma.
Ma S; Kanai R; Pobbati AV; Li S; Che K; Seavey CN; Hallett A; Burtscher A; Lamar JM; Rubin BP
Clin Cancer Res; 2022 Jul; 28(14):3116-3126. PubMed ID: 35443056
[TBL] [Abstract][Full Text] [Related]
95. Substrate Stiffness Influences the Time Dependence of CTGF Protein Expression in Müller Cells.
Davis JT; Foster WJ
Int Physiol J; 2018; 1(1):1. PubMed ID: 30123889
[TBL] [Abstract][Full Text] [Related]
96. GPR35 antagonist CID-2745687 attenuates anchorage-independent cell growth by inhibiting YAP/TAZ activity in colorectal cancer cells.
Otkur W; Liu X; Chen H; Li S; Ling T; Lin H; Yang R; Xia T; Qi H; Piao HL
Front Pharmacol; 2023; 14():1126119. PubMed ID: 37113762
[No Abstract] [Full Text] [Related]
97. Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings.
Fnaiche A; Mélin L; Suárez NG; Paquin A; Vu V; Li F; Allali-Hassani A; Bolotokova A; Allemand F; Gelin M; Cotelle P; Woo S; LaPlante SR; Barsyte-Lovejoy D; Santhakumar V; Vedadi M; Guichou JF; Annabi B; Gagnon A
Bioorg Med Chem Lett; 2023 Oct; 95():129488. PubMed ID: 37770003
[TBL] [Abstract][Full Text] [Related]
98. Prognostic significance of ANO1 expression in cancers.
Zhang C; Li H; Gao J; Cui X; Yang S; Liu Z
Medicine (Baltimore); 2021 Jan; 100(4):e24525. PubMed ID: 33530281
[TBL] [Abstract][Full Text] [Related]
99. GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL.
Liao YY; Chuang YT; Lin HY; Lin NY; Hsu TW; Hsieh SC; Chen ST; Hung JS; Yang HJ; Liang JT; Huang MC; Huang J
Mol Oncol; 2023 Jan; 17(1):119-133. PubMed ID: 36409270
[TBL] [Abstract][Full Text] [Related]
100. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.
Khoo WH; Ledergor G; Weiner A; Roden DL; Terry RL; McDonald MM; Chai RC; De Veirman K; Owen KL; Opperman KS; Vandyke K; Clark JR; Seckinger A; Kovacic N; Nguyen A; Mohanty ST; Pettitt JA; Xiao Y; Corr AP; Seeliger C; Novotny M; Lasken RS; Nguyen TV; Oyajobi BO; Aftab D; Swarbrick A; Parker B; Hewett DR; Hose D; Vanderkerken K; Zannettino ACW; Amit I; Phan TG; Croucher PI
Blood; 2019 Jul; 134(1):30-43. PubMed ID: 31023703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
